RICHMOND, Virginia, September 23, 2014 – algorithmRx, headquartered in Richmond, Virginia, was selected by the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to give presentations at NHLBI’s Regional Innovation Conference in Research Triangle Park.
This by-invitation-only conference brings together small businesses, angel investors, venture capitalists, strategic partners and business leaders from the biotech and pharmaceutical industries. The conference features presentations by select NHLBI-funded companies with innovative technologies, and also includes a panel of biotech-oriented investors, industry leaders and NHLBI representatives.
algorithmRx was one of a select group of NHLBI-funded companies asked to present, which featured the company’s unique aRx Statin Advisor® technology. This technology is an evidence-based clinical decision-support tool designed to assist clinicians in selecting the most effective statin and dose regimen for patients with high LDL-cholesterol (“LDL-C” or “bad cholesterol”). NHLBI and NIH has funded algorithmRx with recent grants totaling $1.7 million as part of NIH’s Small Business Innovation Research (SBIR) program.
Although algorithmRx is not currently seeking outside investment, the Conference served as an excellent forum for initial review of its technology among key industry thought leaders and investors.
The Company hopes to wrap up research related to its SBIR grant in early 2016 with commercial roll-out of aRx Statin Advisor shortly thereafter.
Based in Richmond, Virginia, algorithmRx, LLC develops and delivers innovative healthcare algorithms at the point of care. Our computer-based clinical decision-support systems (CDSS) provide busy clinicians with adaptive, evidence-based guidance to enhance medication management of common chronic health conditions.
Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under SBIR Phase I (1 R43 HL117553-01) and SBIR Phase II (2 R44 HL117553-02 and 5 R44 HL117553-03) awards.